{"pageContent": "Context: Recent demonstration of efficacy with the use of chemohormonal therapy for men with metastatic prostate cancer (mPCa) has expanded the therapeutic options for these patients. Furthermore, multimodal therapy to treat systemic disease in the context of locoregional control has gained increasing interest. Concomitantly, the role of radical prostatectomy (RP) in multimodal treatment for locally advanced prostate cancer is expanding. As a result, there is interest in investigating the potential benefit of cytoreductive RP in mPCa.", "metaData": {"source": "From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/20690063/"}}